Decibel Therapeutics (NASDAQ:DBTX – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $23.00 price objective on the stock. HC Wainwright also issued estimates for Decibel Therapeutics’ FY2027 earnings at ($0.52) EPS.
Other analysts have also issued reports about the company. SVB Securities lowered Decibel Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $7.00 to $2.00 in a report on Wednesday. SVB Leerink cut their price target on Decibel Therapeutics from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Monday, January 23rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Decibel Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.80.
Decibel Therapeutics Price Performance
Shares of Decibel Therapeutics stock opened at $3.73 on Wednesday. The firm has a market cap of $93.14 million, a price-to-earnings ratio of -1.57 and a beta of -0.02. The stock’s 50-day moving average is $3.65 and its 200-day moving average is $3.48. Decibel Therapeutics has a one year low of $1.61 and a one year high of $5.78.
Institutional Trading of Decibel Therapeutics
Decibel Therapeutics Company Profile
Decibel Therapeutics, Inc, a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin.
- Get a free copy of the StockNews.com research report on Decibel Therapeutics (DBTX)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Decibel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decibel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.